Anvumetostat not checked

Amgen · AMG 193 · MTA Cooperative PRMT5 inhibitor

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
5 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Comparator Anvumetostat test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator Anvumetostat test tablet.”In the company’s words, NCT05094336 on ClinicalTrials.gov
Tested for
MTAP-deleted NSCLC, Advanced MTAP-null Solid Tumors, Thoracic Tumors, Non-small Cell Lung Cancer, Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Main trialPhase 2
“The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).”In the company’s words, NCT06593522 on ClinicalTrials.gov
Other names
AMG 193 · MTA Cooperative PRMT5 inhibitor

Other drugs for MTAP-deleted NSCLC

All 2438 drugs for MTAP-deleted NSCLC

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 31 Oct 2026 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Phase 1/2Active, not recruiting 30 Nov 2026 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Phase 1Active, not recruiting 31 Oct 2026 Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1Active, not recruiting 31 Oct 2026 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Phase 1/2Completed 25 Feb 2026 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Anvumetostat

Following is part of Solo: you see every change to Anvumetostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in